We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders.
- Authors
Buch, M. H.; Bingham, S. J.; Bryer, D.; Emery, P.
- Abstract
Objective. Patients may cease therapy with anti-tumour necrosis factor (TNF) agents due to inefficacy at 12 weeks (termed primary non-response) or later. Until now, the extent of this later secondary non-response has not been clearly defined. We followed-up a substantial single-centre cohort to determine kinetics of this secondary loss of response. The licensed dose of 3 mg/kg was used throughout.
- Subjects
INFLIXIMAB; TUMOR necrosis factors; THERAPEUTICS; CYTOKINES; DRUG efficacy; TUMOR treatment
- Publication
Rheumatology, 2007, Vol 46, Issue 7, p1153
- ISSN
1462-0324
- Publication type
Article
- DOI
10.1093/rheumatology/kem075